McKesson Corporation

McKesson managed an all-around beat in the last quarter, closing out a solid fiscal 2023 with full-year revenues of $277 billion and adjusted earnings per diluted share of $25.94. The core Pharmaceutical Distribution business supported growth in the U.S. Pharmaceutical segment, and they divested their European operations to streamline their portfolio. McKesson focused on people and culture, aiming to be the best workplace in the healthcare industry. They also expanded their oncology and biopharma platforms, achieving growth and enhancing medication access. Moreover, McKesson prioritized sustainability and portfolio optimization while striving for positive impacts and health outcomes. Their management is confident in sustaining growth in the coming quarters. We give McKesson Corporation a ‘Hold’ rating with a revised target price.